IBRX logo

ImmunityBio, Inc. (IBRX)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

ImmunityBio, Inc. (IBRX) trades at $7.38 with AI Score 46/100 (Weak). ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for cancers and infectious diseases. Market cap: 8B, Sector: Healthcare.

Last analyzed: Feb 9, 2026
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for cancers and infectious diseases. They utilize immunotherapy and cell therapy platforms, with therapeutic agents in Phase II or III clinical trials.
46/100 AI Score Target $11.33 (+53.5%) MCap 8B Vol 28M

ImmunityBio, Inc. (IBRX) Healthcare & Pipeline Overview

CEORichard Gerald Adcock
Employees671
HeadquartersSan Diego, CA, US
IPO Year2015

ImmunityBio pioneers next-generation immunotherapies and vaccines targeting cancers and infectious diseases, leveraging its innovative cell therapy platforms and strategic collaborations to address unmet medical needs and drive shareholder value in a rapidly evolving biotechnology landscape.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 9, 2026

Investment Thesis

ImmunityBio presents a notable research candidate due to its innovative immunotherapy platforms and promising clinical pipeline. The company's focus on addressing unmet needs in cancer and infectious diseases positions it for significant growth in a rapidly expanding market. With multiple therapeutic agents in Phase II and III clinical trials, ImmunityBio has the potential to generate substantial revenue upon successful commercialization. The company's strategic collaborations and licensing agreements further enhance its technological capabilities and market reach. A gross margin of 94.8% showcases the potential for high profitability. Investors may want to evaluate the inherent risks associated with clinical-stage biotechnology companies, but the potential rewards could be substantial.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market Cap of $5.96B reflects investor confidence in ImmunityBio's potential.
  • Gross Margin of 94.8% indicates strong pricing power and efficient operations.
  • Beta of 0.02 suggests the stock is significantly less volatile than the overall market.
  • Focus on immunotherapy and cell therapy platforms positions ImmunityBio in a high-growth area of biotechnology.
  • Multiple therapeutic agents in Phase II and III clinical trials offer potential for near-term revenue generation.

Competitors & Peers

Strengths

  • Innovative immunotherapy platforms.
  • Promising clinical pipeline.
  • Strategic collaborations.
  • Strong gross margin.

Weaknesses

  • Clinical-stage company with no approved products.
  • High operating expenses.
  • Negative profit margin.
  • Dependence on clinical trial outcomes.

Catalysts

  • Upcoming: Data readouts from ongoing Phase II and III clinical trials.
  • Upcoming: Potential FDA approval of lead therapeutic candidates.
  • Ongoing: Expansion of strategic collaborations and licensing agreements.
  • Ongoing: Advancement of new therapies into clinical development.

Risks

  • Potential: Clinical trial failures could significantly impact the company's value.
  • Potential: Regulatory delays or rejection could delay or prevent commercialization.
  • Ongoing: Competition from larger pharmaceutical companies with greater resources.
  • Potential: Intellectual property challenges could threaten the company's competitive advantage.

Growth Opportunities

  • Expansion of Clinical Pipeline: ImmunityBio can expand its clinical pipeline by advancing existing therapeutic agents through clinical trials and developing new therapies based on its innovative technology platforms. The market for cancer therapies is estimated to reach hundreds of billions of dollars by 2030, providing a significant opportunity for ImmunityBio to capture market share with successful products. This is an ongoing opportunity.
  • Strategic Collaborations and Licensing Agreements: ImmunityBio can leverage strategic collaborations and licensing agreements to expand its technological capabilities, accelerate drug development, and broaden its market reach. Collaborations with leading research institutions and pharmaceutical companies can provide access to new technologies, funding, and expertise. This is an ongoing opportunity.
  • Commercialization of Approved Therapies: Upon successful completion of clinical trials and regulatory approval, ImmunityBio can generate significant revenue by commercializing its therapies. The market for infectious disease vaccines is also substantial, offering further growth potential. This is an upcoming opportunity.
  • Geographic Expansion: ImmunityBio can expand its operations into new geographic markets, such as Europe and Asia, to increase its customer base and revenue streams. These markets offer significant growth potential due to their large populations and increasing healthcare spending. This is an ongoing opportunity.
  • Acquisition of Complementary Technologies or Companies: ImmunityBio can acquire complementary technologies or companies to enhance its product portfolio, expand its technological capabilities, and gain access to new markets. Strategic acquisitions can accelerate growth and create synergies. This is an ongoing opportunity.

Opportunities

  • Expansion of clinical pipeline.
  • Commercialization of approved therapies.
  • Geographic expansion.
  • Acquisition of complementary technologies.

Threats

  • Clinical trial failures.
  • Regulatory hurdles.
  • Competition from established pharmaceutical companies.
  • Patent challenges.

Competitive Advantages

  • Proprietary immunotherapy platforms.
  • Extensive patent portfolio.
  • Strategic collaborations with leading institutions.
  • Experienced management team.

About IBRX

Founded in 2014 and headquartered in San Diego, California, ImmunityBio, Inc. is a clinical-stage biotechnology company committed to developing innovative therapies and vaccines that bolster the body's natural immune system to combat cancer and infectious diseases. The company's core focus lies in harnessing the power of immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. These platforms serve as the foundation for developing a diverse pipeline of therapeutic agents currently undergoing Phase II and III clinical trials. ImmunityBio's research and development efforts target a wide range of liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as life-threatening pathogens like SARS-CoV-2 and HIV. The company has established strategic collaboration agreements with renowned institutions like the National Cancer Institute and the National Institute of Deafness and Communication Disorders, alongside partnerships with Amyris, Inc. Furthermore, ImmunityBio has forged license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc., to expand its technological capabilities and accelerate the development of novel therapies.

What They Do

  • Develops immunotherapies and vaccines for cancers.
  • Creates therapies for infectious diseases.
  • Utilizes antibody cytokine fusion proteins.
  • Develops synthetic immunomodulators.
  • Creates vaccine technologies.
  • Harnesses natural killer cells for therapeutic purposes.
  • Employs adaptive (T cell) immune systems.

Business Model

  • Develops and patents novel immunotherapies and vaccines.
  • Conducts clinical trials to demonstrate safety and efficacy.
  • Seeks regulatory approval from agencies like the FDA.
  • Commercializes approved therapies through sales and marketing.

Industry Context

ImmunityBio operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and significant investment in research and development. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by increasing demand for novel therapies and personalized medicine. ImmunityBio's focus on immunotherapy and cell therapy aligns with key industry trends, as these approaches are gaining prominence in cancer treatment and infectious disease management. Competitors like AGIO, BEAM, COGT, DNLI, and ETNB are also vying for market share, but ImmunityBio's unique technology platforms and clinical pipeline differentiate it within the competitive landscape.

Key Customers

  • Patients suffering from cancer.
  • Individuals at risk of infectious diseases.
  • Healthcare providers and hospitals.
  • Research institutions and government agencies.
AI Confidence: 71% Updated: Feb 9, 2026

Financials

Chart & Info

ImmunityBio, Inc. (IBRX) stock price: $7.38 (-0.69, -8.55%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IBRX.

Price Targets

Consensus target: $11.33

MoonshotScore

46/100

What does this score mean?

The MoonshotScore rates IBRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Biotechnology

Competitors & Peers

Latest News

Latest ImmunityBio, Inc. Analysis

ImmunityBio, Inc. Stock: Key Questions Answered

What does ImmunityBio, Inc. do?

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that activate the immune system to fight cancer and infectious diseases. The company's core technology revolves around its immunotherapy and cell therapy platforms, which are designed to stimulate the body's natural defenses. ImmunityBio is currently conducting clinical trials for several therapeutic candidates targeting various types of cancer and infectious diseases. The company aims to address unmet medical needs and improve patient outcomes through its innovative approach to immunotherapy.

Is IBRX stock worth researching?

IBRX stock presents a speculative investment opportunity with high potential rewards and significant risks. The company's innovative immunotherapy platforms and promising clinical pipeline offer substantial growth potential. However, as a clinical-stage company with no approved products, ImmunityBio is subject to the inherent risks of clinical trial failures and regulatory hurdles. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in IBRX. The company's high gross margin of 94.8% is encouraging, but the negative profit margin highlights the need for successful commercialization of its therapies.

What are the main risks for IBRX?

The primary risks for IBRX include the potential for clinical trial failures, regulatory delays or rejection, competition from established pharmaceutical companies, and intellectual property challenges. Clinical trial failures could significantly impact the company's value and delay or prevent the commercialization of its therapies. Regulatory hurdles could also delay or prevent the approval of its therapeutic candidates. Competition from larger pharmaceutical companies with greater resources poses a significant threat. Intellectual property challenges could threaten the company's competitive advantage and market position.

What are the key factors to evaluate for IBRX?

ImmunityBio, Inc. (IBRX) currently holds an AI score of 46/100, indicating low score. Analysts target $11.33 (+54% from $7.38). Key strength: Innovative immunotherapy platforms.. Primary risk to monitor: Potential: Clinical trial failures could significantly impact the company's value.. This is not financial advice.

How frequently does IBRX data refresh on this page?

IBRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven IBRX's recent stock price performance?

Recent price movement in ImmunityBio, Inc. (IBRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $11.33 implies 54% upside from here. Notable catalyst: Innovative immunotherapy platforms.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider IBRX overvalued or undervalued right now?

Determining whether ImmunityBio, Inc. (IBRX) is overvalued or undervalued requires examining multiple metrics. Analysts target $11.33 (+54% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying IBRX?

Before investing in ImmunityBio, Inc. (IBRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment in biotechnology companies is inherently risky.
  • This analysis is for informational purposes only and does not constitute investment advice.
Data Sources

Popular Stocks